Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김경진 | * |
dc.date.accessioned | 2023-07-31T16:31:13Z | - |
dc.date.available | 2023-07-31T16:31:13Z | - |
dc.date.issued | 2023 | * |
dc.identifier.issn | 0735-1097 | * |
dc.identifier.other | OAK-33533 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/265326 | - |
dc.description.abstract | Background: The routine use of high-intensity statins should be considered carefully in elderly patients because of their higher risk of intolerance or adverse events. Objectives: We evaluated the impact of moderate-intensity statin with ezetimibe combination therapy compared with high-intensity statin monotherapy in elderly patients with atherosclerotic cardiovascular disease (ASCVD). Methods: In this post hoc analysis of the RACING (RAndomized Comparison of Efficacy and Safety of Lipid-lowerING With Statin Monotherapy Versus Statin/Ezetimibe Combination for High-risk Cardiovascular Diseases) trial, patients were stratified by age (≥75 years and <75 years). The primary endpoint was a 3-year composite of cardiovascular death, major cardiovascular events, or nonfatal stroke. Results: Among the 3,780 enrolled patients, 574 (15.2%) were aged ≥75 years. The rates of the primary endpoint were not different between the moderate-intensity statin with ezetimibe combination therapy group and the high-intensity statin monotherapy group among patients aged ≥75 years (10.6% vs 12.3%; HR: 0.87; 95% CI: 0.54-1.42; P = 0.581) and those <75 years (8.8% vs 9.4%; HR: 0.94; 95% CI: 0.74-1.18; P = 0.570) (P for interaction = 0.797). Moderate-intensity statin with ezetimibe combination therapy was associated with lower rates of intolerance-related drug discontinuation or dose reduction among patients aged ≥75 years (2.3% vs 7.2%; P = 0.010) and those <75 years (5.2% vs 8.4%; P < 0.001) (P for interaction = 0.159). Conclusions: Moderate-intensity statin with ezetimibe combination therapy showed similar cardiovascular benefits to those of high-intensity statin monotherapy with lower intolerance-related drug discontinuation or dose reduction in elderly patients with ASCVD having a higher risk of intolerance, nonadherence, and discontinuation with high-intensity statin therapy. (RAndomized Comparison of Efficacy and Safety of Lipid-lowerING With Statin Monotherapy Versus Statin/Ezetimibe Combination for High-risk Cardiovascular Diseases [RACING Trial]; NCT03044665) © 2023 American College of Cardiology Foundation | * |
dc.language | English | * |
dc.publisher | Elsevier Inc. | * |
dc.subject | atherosclerotic cardiovascular disease | * |
dc.subject | elderly | * |
dc.subject | ezetimibe | * |
dc.subject | statin | * |
dc.title | Combination Moderate-Intensity Statin and Ezetimibe Therapy for Elderly Patients With Atherosclerosis | * |
dc.type | Article | * |
dc.relation.issue | 14 | * |
dc.relation.volume | 81 | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.startpage | 1339 | * |
dc.relation.lastpage | 1349 | * |
dc.relation.journaltitle | Journal of the American College of Cardiology | * |
dc.identifier.doi | 10.1016/j.jacc.2023.02.007 | * |
dc.identifier.wosid | WOS:000994785900001 | * |
dc.identifier.scopusid | 2-s2.0-85151439848 | * |
dc.author.google | Lee S.-H. | * |
dc.author.google | Lee Y.-J. | * |
dc.author.google | Heo J.H. | * |
dc.author.google | Hur S.-H. | * |
dc.author.google | Choi H.H. | * |
dc.author.google | Kim K.-J. | * |
dc.author.google | Kim J.H. | * |
dc.author.google | Park K.-H. | * |
dc.author.google | Lee J.H. | * |
dc.author.google | Choi Y.J. | * |
dc.author.google | Lee S.-J. | * |
dc.author.google | Hong S.-J. | * |
dc.author.google | Ahn C.-M. | * |
dc.author.google | Kim B.-K. | * |
dc.author.google | Ko Y.-G. | * |
dc.author.google | Choi D. | * |
dc.author.google | Hong M.-K. | * |
dc.author.google | Jang Y. | * |
dc.author.google | Kim J.-S. | * |
dc.contributor.scopusid | 김경진(57190021870) | * |
dc.date.modifydate | 20240426120924 | * |